Compare WINA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | NUVB |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.4B |
| IPO Year | 1993 | N/A |
| Metric | WINA | NUVB |
|---|---|---|
| Price | $426.96 | $8.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 84.2K | ★ 10.2M |
| Earning Date | 10-15-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | ★ $84,517,400.00 | $26,748,000.00 |
| Revenue This Year | $7.05 | $283.17 |
| Revenue Next Year | $3.60 | $340.98 |
| P/E Ratio | $38.01 | ★ N/A |
| Revenue Growth | 3.35 | ★ 1137.19 |
| 52 Week Low | $295.79 | $1.54 |
| 52 Week High | $527.37 | $8.70 |
| Indicator | WINA | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 76.08 |
| Support Level | $405.86 | $7.46 |
| Resistance Level | $432.21 | $8.24 |
| Average True Range (ATR) | 15.68 | 0.62 |
| MACD | 2.91 | 0.13 |
| Stochastic Oscillator | 68.18 | 97.20 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.